Market cap
$26,632 Mln
Recently Viewed
Clear AllMarket cap
$26,632 Mln
Revenue (TTM)
$3,644 Mln
P/E Ratio
61.9
P/B Ratio
5.1
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$438 Mln
ROE
0.1 %
ROCE
7 %
Industry P/E
--
EV/EBITDA
24.6
Debt to Equity
0.5
Book Value
$--
EPS
$1.9
Face value
--
Shares outstanding
228,995,008
CFO
$4,286.77 Mln
EBITDA
$3,654.70 Mln
Net Profit
$994.17 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Horizon Pharma PLC (HZNP)
| 2.2 | 0.8 | 13.2 | 78.9 | 11.7 | 45.0 | 40.8 |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Horizon Pharma PLC (HZNP)
| 5.6 | 47.3 | 102.1 | 85.3 | 33.6 | -9.8 | -25.3 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its... portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland. Read more
Chairman, Pres & CEO
Mr. Timothy P. Walbert
Chairman, Pres & CEO
Mr. Timothy P. Walbert
Headquarters
Dublin
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Horizon Pharma PLC (HZNP) is $116.30 (NASDAQ) as of 09-Oct-2023 09:30 EDT. Horizon Pharma PLC (HZNP) has given a return of 11.7% in the last 3 years.
The P/E ratio of Horizon Pharma PLC (HZNP) is 61.86 times as on 09-Oct-2023.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
50.85
|
5.23
|
|
2021
|
47.74
|
5.46
|
|
2020
|
43.70
|
4.23
|
|
2019
|
13.33
|
3.49
|
|
2018
|
-45.89
|
3.23
|
The 52-week high and low of Horizon Pharma PLC (HZNP) are Rs -- and Rs -- as of 27-Apr-2026.
Horizon Pharma PLC (HZNP) has a market capitalisation of $ 26,632 Mln as on 09-Oct-2023. As per SEBI classification, it is a company.
Before investing in Horizon Pharma PLC (HZNP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.